Repligen Corporation (NASDAQ: RGEN) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Repligen Corporation to similar companies based on the strength of its profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Profitability

This table compares Repligen Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repligen Corporation 15.61% 9.90% 5.93%
Repligen Corporation Competitors -540.25% -41.76% -24.70%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Repligen Corporation and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen Corporation 0 2 2 0 2.50
Repligen Corporation Competitors 98 368 966 28 2.63

Repligen Corporation currently has a consensus target price of $41.00, suggesting a potential downside of 7.72%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 26.89%. Given Repligen Corporation’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Repligen Corporation has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Repligen Corporation and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Repligen Corporation $113.32 million $29.54 million 87.12
Repligen Corporation Competitors $2.40 billion $905.93 million 2.88

Repligen Corporation’s rivals have higher revenue and earnings than Repligen Corporation. Repligen Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

97.9% of Repligen Corporation shares are owned by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Repligen Corporation has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Repligen Corporation’s rivals have a beta of 0.81, meaning that their average stock price is 19% less volatile than the S&P 500.

Summary

Repligen Corporation rivals beat Repligen Corporation on 7 of the 13 factors compared.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.